Pharmafile Logo
Pharmafocus logo
Advanced Search
asthma inhalers

GSK suffers Breo late-stage trial blow

September 9, 2015
Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III

GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …

News
michael_koslowski_picture

Mission Therapeutics appoints new chief medical officer

September 9, 2015
Medical Communications, Research and Development Dr Michael Koslowski, Mission Therapeutics

Mission Therapeutics has announced the appointment of Dr Michael Koslowski as chief medical officer. Dr Koslowski brings over 15 years’ …

Appointment
unisa_research_building

Yabao Pharmaceutical and UniSA embark on joint venture

September 9, 2015
Research and Development Cancer, Yabao Pharmaceutical

Yabao Pharmaceutical and the University of South Australia (UniSA) have joined together in a collaboration to develop new treatments for …

News

Biocair International Ltd achieves AEO approval

September 8, 2015
Medical Communications Biocair

We are pleased to announce that as of 8th September 2015 Biocair International Ltd is an Authorised Economic Operator (AEO). …

News
Press release

Sun Pharma strengthens opiates business

September 8, 2015
Manufacturing and Production Australia, GSK, Sun Pharma, manufacturing and production, opiates

Sun Pharmaceutical Industries has strengthened its global opiates manufacturing business with the acquisition of two Australian manufacturing facilities from GlaxoSmithKline. …

News
avastin

New treatment option for ovarian cancer patients in Scotland

September 8, 2015
Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer

The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …

News
Europe flag

EMA launches project to boost early patient access to drugs

September 8, 2015
Research and Development EMA, European Medicines Agency, MAPPs, adaptive pathways, drug development, market access

The EMA is launching an adaptive pathway project to bring new medicinal products to market in Europe.  The ADAPT SMART …

News
novo_nordisk_new_hillerod_facility

Novo Nordisk expands in Denmark

September 8, 2015
Manufacturing and Production, Research and Development Denmark, Novo Nordisk, haemophilia API

Novo Nordisk has announced that the company is investing 500 million Danish kroner (about £48.8 million) in a new 19,000 …

News
massachusetts_institute_of_technology_7194419730

Novo joins forces with MIT innovating drug devices

September 8, 2015
Manufacturing and Production, Research and Development Novo Nordisk

Novo Nordisk has initiated a research collaboration with the Langer Laboratory at the Massachusetts Institute of Technology for what is …

News
mehwish_abdeali

Wave appoints Mehwish Abdeali as senior programme executive

September 8, 2015
Medical Communications Mehwish Abdeali, wave

Mehwish Abdeali has been appointed as senior programme executive at Wave, a specialist medical education company. Mehwish joins Wave from …

Appointment
ABPI image

ABPI ‘deeply concerned’ by slow UK drugs uptake

September 7, 2015
Sales and Marketing ABPI, PPRS, Pharmaceutical Price Regulation Scheme, drugs bill, market access, medicines bill

The UK pharma industry paid £209 million to underwrite the UK medicines bill in second quarter of 2015, according to …

News
keytruda

NICE recommends Keytruda for advanced skin cancer

September 7, 2015
Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer

NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS.  …

News
healthcareusnow

Pharma industry to deliver strong growth – despite price pressure

September 7, 2015
Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry

The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …

News
neuron

Neurology comes to the fore

September 7, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …

Feature
revlimid_celgene

Celgene threatens to scale back UK clinical trial investment after CDF snub

September 4, 2015
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …

News
pfizer_hq_new_york

Pfizer completes $15 billion Hospira acquisition

September 4, 2015
Biosimilar Drugs, Hospira, Pfizer, mergers and acquisitions

Pfizer has completed its acquisition of Illinois-based injectable drugs and infusion device specialist Hospira for around $15 billion.The deal, first announced …

News

Genentech Haemophilia therapy gets FDA breakthrough designation

September 4, 2015
Research and Development, Sales and Marketing Genentech, Roche, haemophilia a

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …

News
NHS sign

Companies braced for new round of cancer cuts

September 4, 2015
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts

Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …

News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015
Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026